Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary(R)): Results of a Nationwide Dose Conversion Survey

被引:2
作者
Hauser, Robert A. [1 ]
Banisadr, Ghazal [2 ]
Vuong, Kara [2 ]
Freilich, David [2 ]
Fisher, Stanley [2 ]
D'Souza, Richard [2 ]
机构
[1] Univ S Florida, Tampa, FL 33620 USA
[2] Amneal Pharmaceut, Bridgewater, NJ USA
关键词
D O I
10.1155/2021/6638088
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background. The introduction of carbidopa-levodopa extended-release (CD-LD ER) capsules (Rytary (R)) did not go as smoothly as expected, largely due to difficulty around dose conversion from available immediate-release (IR) levodopa (LD) formulations. The dose conversion table in the CD-LD ER prescribing information was similar to the table used in the pivotal clinical trial and is considered by many prescribing HCPs to be less than optimal. By the end of the dose conversion period in that trial, dosing in 76% of subjects was adjusted for symptom control; roughly 60% of patients required a higher dose and about half required more frequent administration than the recommended TID dosing. Objective. The primary objective of our nationwide (US) survey was to determine the dose conversion strategy most commonly employed by CD-LD ER frequent prescribers. The survey also aimed to explore additional features regarding CD-LD ER use in clinical practice. Methods. A survey consisting of 21 multiple-choice questions was developed and administered to experts in the use of CD-LD ER, based on prescription volume. Results. Of the 394 HCPs who were invited to participate, 90 (23%) HCPs completed the survey. All respondents were aware of the dose conversion table; the largest group did not find the table to be helpful and did not use it to convert patients to CD-LD ER. The most common strategy in calculating the CD-LD ER dose was based on the total daily LD IR dose, with the majority of that group initiating dose conversion by doubling the total daily LD dose from CD-LD IR and administering CD-LD ER one less time per day. Conclusion. Overall, most survey respondents agreed that a good starting point for CD-LD ER conversion could be doubling the daily LD IR dose and administering it one time less frequently. Moreover, rapid patient follow-up after initial dose conversion to allow for further dose adjustments plays a critical role in achieving success. Gaining experience over time is important for satisfactory conversion.
引用
收藏
页数:9
相关论文
共 7 条
[1]  
Espay AJ, 2017, NEUROL-CLIN PRACT, V7, P86, DOI 10.1212/CPJ.0000000000000316
[2]  
Hauser RA., 2015, Clin. Med. J, V1, P34
[3]   Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial [J].
Hauser, Robert A. ;
Hsu, Ann ;
Kell, Sherron ;
Espay, Alberto J. ;
Sethi, Kapil ;
Stacy, Mark ;
Ondo, William ;
O'Connell, Martin ;
Gupta, Suneel .
LANCET NEUROLOGY, 2013, 12 (04) :346-356
[4]   Crossover Comparison of IPX066 and a Standard Levodopa Formulation in Advanced Parkinson's Disease [J].
Hauser, Robert A. ;
Ellenbogen, Aaron L. ;
Metman, Leo Verhagen ;
Hsu, Ann ;
O'Connell, Martin J. ;
Modi, Nishit B. ;
Yao, Hsuan-Ming ;
Kell, Sherron H. ;
Gupta, Suneel K. .
MOVEMENT DISORDERS, 2011, 26 (12) :2246-2252
[5]   Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet®), sustained-release carbidopa-levodopa (Sinemet® CR), and carbidopa-levodopa-entacapone (Stalevo®) [J].
Hsu, Ann ;
Yao, Hsuan-Ming ;
Gupta, Suneel ;
Modi, Nishit B. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (09) :995-1003
[6]   Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa-Levodopa [J].
Mittur, Aravind ;
Gupta, Suneel ;
Modi, Nishit B. .
CLINICAL PHARMACOKINETICS, 2017, 56 (09) :999-1014
[7]   Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials [J].
Nausieda, Paul A. ;
Hsu, Ann ;
Elmer, Lawrence ;
Gil, Ramon A. ;
Spiegel, Joerg ;
Singer, Carlos ;
Khanna, Sarita ;
Rubens, Robert ;
Kell, Sherron ;
Modi, Nishit B. ;
Gupta, Suneel .
JOURNAL OF PARKINSONS DISEASE, 2015, 5 (04) :837-845